JPRN-UMIN000039666尚未招募未知
Biomarker Study for Combined nivolumab and ipilimumab in Fecal microbiota metabolites of Advanced malignant melanoma - SCFA study
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who are considered inappropriate for the investigator to participate in the study are excluded.
研究者
相似试验
已完成
不适用
Biomarker analysis: Phase II study of nivolumab + abemaciclib + endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer (NEWFLAME) WJOG11418B-TRHormone receptor positive and HER2-negative advanced breast cancerJPRN-UMIN000036970West Japan Oncology Group53
进行中（未招募）
1 期
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA)Stage IV Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001195-35-ESBristol-Myers Squibb International Corporation504
进行中（未招募）
1 期
A Study of Nivolumab and Ipilimumab Combined with Chemotherapy Compared to Chemotherapy by Itself as the First Treatment Given for Stage IV Non-Small Cell Lung Cancer (NSCLC) (CheckMate 9LA)Stage IV Non-Small Cell Lung Cancer (NSCLC)MedDRA version: 20.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001195-35-FRBristol-Myers Squibb International Corporation504
终止
2 期
Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLCNon-small Cell Lung CancerNCT03425331Dana-Farber Cancer Institute5
招募中
2 期
A phase II study of ipilimumab, nivolumab, and radiotherapy for advanced NSCLCJPRN-jRCTs021220003Miyauchi Eisaku40